NASDAQ: NSPR
Inspiremd Inc Stock

$2.32-0.18 (-7.2%)
Updated Jun 13, 2025
NSPR Price
$2.32
Fair Value Price
N/A
Market Cap
$71.07M
52 Week Low
$2.07
52 Week High
$3.80
P/E
-2.97x
P/B
2.51x
P/S
19.14x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.03M
Earnings
-$36.14M
Gross Margin
21.4%
Operating Margin
-513.45%
Profit Margin
-514.3%
Debt to Equity
0.36
Operating Cash Flow
-$26M
Beta
0.48
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

NSPR Overview

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine NSPR's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
C
NSPR
Ranked
Unranked of 108

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$29.39A
$12.10A
$20.07A
View Top Medical Device Stocks

Be the first to know about important NSPR news, forecast changes, insider trades & much more!

NSPR News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NSPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NSPR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NSPR is good value based on its book value relative to its share price (2.51x), compared to the US Medical Devices industry average (3.99x)
P/B vs Industry Valuation
NSPR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NSPR due diligence checks available for Premium users.

Valuation

NSPR price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-2.97x
Industry
35.6x
Market
31.36x

NSPR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.51x
Industry
3.99x
NSPR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NSPR's financial health

Profit margin

Revenue
$1.5M
Net Income
-$11.2M
Profit Margin
-730.3%
NSPR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NSPR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$38.7M
Liabilities
$10.3M
Debt to equity
0.36
NSPR's short-term assets ($32.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NSPR's short-term assets ($32.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NSPR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NSPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$8.8M
Investing
$1.7M
Financing
$506.0k
NSPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NSPR vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
NSPR$71.07M-7.20%-2.97x2.51x
ELUT$73.19M-5.82%-1.26x-2.01x
CTSO$68.25M+1.87%-3.89x4.69x
TELAD$67.24M-8.11%-1.26x3.71x
APYX$66.14M+2.04%-3.18x6.29x

Inspiremd Stock FAQ

What is Inspiremd's quote symbol?

(NASDAQ: NSPR) Inspiremd trades on the NASDAQ under the ticker symbol NSPR. Inspiremd stock quotes can also be displayed as NASDAQ: NSPR.

If you're new to stock investing, here's how to buy Inspiremd stock.

What is the 52 week high and low for Inspiremd (NASDAQ: NSPR)?

(NASDAQ: NSPR) Inspiremd's 52-week high was $3.80, and its 52-week low was $2.07. It is currently -38.92% from its 52-week high and 12.08% from its 52-week low.

How much is Inspiremd stock worth today?

(NASDAQ: NSPR) Inspiremd currently has 30,635,346 outstanding shares. With Inspiremd stock trading at $2.32 per share, the total value of Inspiremd stock (market capitalization) is $71.07M.

Inspiremd stock was originally listed at a price of $54,862,527.43 in Apr 12, 2011. If you had invested in Inspiremd stock at $54,862,527.43, your return over the last 14 years would have been -100%, for an annualized return of -70.26% (not including any dividends or dividend reinvestments).

How much is Inspiremd's stock price per share?

(NASDAQ: NSPR) Inspiremd stock price per share is $2.32 today (as of Jun 13, 2025).

What is Inspiremd's Market Cap?

(NASDAQ: NSPR) Inspiremd's market cap is $71.07M, as of Jun 15, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Inspiremd's market cap is calculated by multiplying NSPR's current stock price of $2.32 by NSPR's total outstanding shares of 30,635,346.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.